Levomepromazine
This phenothiazine antipsychotic and sedative is used to treat psychosis, severe anxiety, agitation, and to provide pain relief and sedation in palliative care settings. It has both antipsychotic and antiemetic properties, making it useful for nausea and vomiting as well.
น้ำหนักโมเลกุล
328.5000 g/mol
LogP
4.70
TPSA
41.00 Ų
Lipinski RO5
ผ่าน
ด้านการรักษา
กลไกการออกฤทธิ์
Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …
โครงสร้าง 2 มิติ
Cite this structure
Embed this structure
SMILES
COc1ccc2c(c1)N(C[C@H](C)CN(C)C)c1ccccc1S2
InChI
InChI=1S/C19H24N2OS/c1-14(12-20(2)3)13-21-16-7-5-6-8-18(16)23-19-10-9-15(22-4)11-17(19)21/h5-11,14H,12-13H2,1-4H3/t14-/m1/s1
Molecular Formula
C19H24N2OS
HBD / HBA
- / 4
พันธะที่หมุนได้
5
อะตอมหนัก
23
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
คำถามที่พบบ่อย
This phenothiazine antipsychotic and sedative is used to treat psychosis, severe anxiety, agitation, and to provide pain relief and sedation in palliative care settings. It has both antipsychotic and antiemetic properties, making it useful for nausea and vomiting as well.
Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.
Yes, Levomepromazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1764. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 72287. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
ข้อจำกัดความรับผิดชอบทางการแพทย์
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="levomepromazine"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/levomepromazine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/levomepromazine/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/levomepromazine/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="levomepromazine"></drugfyi-drug>